Purpose: We sought to determine the efficacy of genetically distinct bacillus Calmette-Gu erin strains in preventing disease recurrence in patients with nonmuscle invasive bladder cancer. Materials and Methods: We conducted a systematic review and network metaanalysis of trials evaluating bacillus Calmette-Gu erin strains against all possible comparators (different bacillus Calmette-Gu erin strains, chemotherapy and nonbacillus Calmette-Gu erin biological therapies) with intravesical chemotherapy as the common comparator. MEDLINEÒ (http://www.ncbi.nlm.nih.gov/ pubmed) served as the primary data source, with the search from inception to October 2016 for clinical trials involving patients with nonmuscle invasive bladder cancer receiving bacillus Calmette-Gu erin. Primary outcome measure was bladder cancer recurrence, defined as recurrent bladder tumor of any grade or stage. Random effect network meta-analysis provided estimates for outcomes and is presented as odds ratios. Results: Across all possible comparators (65 trials, 12,246 patients, 9 strains) there were 2,177 recurrences in 5,642 treated patients (38.6%) and 2,316 recurrences in 5,441 comparators (42.6%). With chemotherapy as the common comparator (28 trials, 5,757 patients, 5 strains) Tokyo-172 (OR 0.39, 95% CI 0.16e0.93), Pasteur (OR 0.49, 95% CI 0.28e0.86) and TICEÒ (OR 0.61, 95% CI 0.40e0.93) strains were significantly better than chemotherapy at preventing recurrence. No bacillus Calmette-Gu erin strain demonstrated significant superiority when compared to any other strain at preventing recurrence in the network meta-analysis. Conclusions: Bacillus Calmette-Gu erin strains exhibited significant differences in efficacy compared to chemotherapy. However, no definitive conclusions could be reached regarding strain superiority, and head-to-head trials are greatly needed to further understand the importance of strain selection in determining bacillus Calmette-Gu erin efficacy. No direct or indirect commercial incentive associated with publishing this article.
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0022-5347/17/1983-0503/0 THE JOURNAL OF UROLOGY family of daughter strains that were originally derived from virulent Mycobacterium bovis. Bacillus Calmette-Gu erin strains have considerable genotypic diversity and elicit variable immune responses. However, it is unclear if these genetic differences influence the oncologic efficacy of this therapy. Understanding the influence of bacillus Calmette-Gu erin strains on bladder cancer recurrence is critical because manufacturing shortages have resulted in episodes of diminished global availability of specific strains. In addition, understanding the effects of different strains on oncologic efficacy could elucidate mechanisms underlying responsiveness to this agent.
Bladder cancer is the fourth most common malignancy in men. In 2016 there were an estimated 76,960 new cases, and bladder cancer accounted for 16,390 deaths in the United States. 1 Most patients diagnosed with bladder cancer present with NMIBC, including CIS and Ta and T1 disease. For these patients the standard initial therapy is complete removal of all papillary lesions via transurethral resection, with bladder preservation possible in most patients. Due to the high rates of disease recurrence, adjuvant therapy with intravesical instillation of BCG is indicated for all high grade and some low grade nonmuscle invasive bladder tumors. 2 The term BCG comprises a family of related strains derived from a virulent strain of M. bovis. Following 13 years of serial in vitro passaging Calmette and Gu erin developed the original BCG strain, which was attenuated yet provided protection against virulent strains including M. bovis. Subsequent to the first use as a tuberculosis vaccine in 1921 BCG cultures were distributed globally for use in vaccine manufacturing. As a result of continuous passages under different conditions in various laboratories throughout the world, BCG strains began to diverge genetically until the introduction of freeze-dried seed lots in the 1960s. As a result, existing BCG vaccine strains have extensive genotypic diversity, including deletions and duplications that can be linked to their dissemination patterns. 3 In some studies genetically distinct strains have been associated with differences in elicited immune responses, including reactogenicity and immunogenicity. 4 However, it is unknown if such differences influence BCG efficacy in the treatment of bladder cancer.
Head-to-head trials comparing BCG suggest that differences in strains can influence clinical outcomes.
5e9 Unfortunately these trials have been relatively small, lacking the statistical power to reliably assess any effect related to strain differences. Therefore, we initiated a systematic review and network meta-analysis to determine if differences in BCG strains are associated with therapeutic response in patients with bladder cancer. This network meta-analysis integrates data from direct comparisons of treatments in trials with indirect comparisons of interventions assessed against a common comparator in different trials, to compare all investigated interventions.
MATERIALS AND METHODS
We conducted a systematic review of MEDLINE from 1966 to October 2016 in adherence to the PRISMA guidelines, 10 Selection of studies to include in the network metaanalysis was based on several criteria, including number of series available for a given comparator, similarity regarding patient populations and study characteristics (transitivity), and availability of head-to-head comparisons. For final analysis only the subset of trials with chemotherapy as the common comparator met these criteria.
Data Collection
A literature search and data extraction from each publication were conducted independently by 3 investigators (BEB, HW, RSS). Data included sample size, number of patients per treatment group, exposure and outcome definitions, study location, type of control, study design, strain type and dose, treatment schedule and summary of results. Any discrepancies were resolved by consensus in a meeting in the presence of a moderator (JEC). Studies were excluded if they had fewer than 10 patients, were case reports, were nonrandomized series or did not contain data on recurrence. Data from cohorts represented in more than 1 publication were only reported once, with the most upto-date information represented. Maintenance therapy with intravesical BCG was defined as any additional treatment(s) following an initial induction dose. Standard doses for all BCG strains are outlined in table 1. Any dose less than the standard dose was designated as "low dose."
Risk of Bias Assessment and Reporting
All of the extracted data were evaluated for internal consistency and contrasted with the trial protocol and all published reports. Data were extracted independently by 2 authors (BEB, JSO). Data were checked for validity, missing values and completeness across all variables according to the criteria defined by Higgins and Green. 12 The process of randomization and concealment was also assessed according to the method described by Higgins and Green. All disagreements were resolved on discussion with the moderator (RSS). The result of this meta-analysis was reported according to the PRISMA statement.
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Statistical Evaluation
The primary study end point was disease recurrence, rather than time to recurrence, defined as pathologically confirmed low and/or high grade bladder cancer at any time following BCG treatment. We did not interpret time to recurrence since the OR fails to account for heterogeneity in exposure times among patients randomized to each study arm. Odds ratios and 95% confidence intervals comparing recurrence rates for BCG strains with chemotherapy were estimated from the individual studies. Thus, the point estimates represent cumulative incidence rather than time to recurrence.
Our initial approach to evaluate the comparative effectiveness among the 10 unique BCG strains was to perform a series of standard pairwise random effect metaanalyses stratified by comparator and strain within comparator. 13 OR was used to measure the relative effectiveness of the BCG strains in reducing recurrence. We grouped the meta-analyses by comparison type, ie BCG vs chemotherapy, BCG plus surgery vs surgery only, BCG induction plus maintenance vs BCG induction only and standard vs low BCG dose. We used the standard 0.5 zero cell continuity correction to account for zero event arms. Standard chi-square test for heterogeneity and I 2 index were used to assess statistical heterogeneity in treatment effects across studies. A significance level of less than 0.15 and/or I 2 greater than 50% was used to determine the presence of statistical heterogeneity. 14 We performed a frequentist random effect network meta-analysis on a subset of 28 trials with chemotherapy as the common comparator.
15e17 This subset was the only one of sufficient size that included head-to-head direct and indirect comparisons to assess the comparative effectiveness among 5 BCG strains (Tokyo-172, Pasteur, TICE, Connaught and RIVM). Two BCG strains, each represented by a single trial, that were excluded from these analyses were 1) a fair quality trial comparing the Glaxo BCG strain with the Pasteur BCG strain (no chemotherapy comparator), 6 and 2) a small, fair quality trial comparing Armand Frappier BCG strain to chemotherapy. 18 The 28 included studies are sufficiently similar regarding patient populations and comparators to ensure sufficient transitivity (similarity) across trials to meaningfully combine direct and indirect effect estimates of the relative effectiveness among the 5 BCG strains. Network meta-analysis also assumes consistency in effect estimates derived from direct head-to-head comparisons among the BCG strains, and indirect comparisons derived based on the contrast between each BCG strain and chemotherapy. We used the method described by Lu and Ades to assess inconsistency between direct and indirect comparison. 19 Results from our network meta-analysis are summarized graphically and in league tables. Primary assessment of comparative effectiveness among the 5 BCG strains is expressed as odds ratios with 95% confidence intervals. Relative rankings among the 5 BCG strains were obtained by computing the SUCRA. 20 SUCRA scores vary between 0 and 1, and they track with the mean rank for each strain based on the probability that a particular strain is ranked best among the comparator strains (rank ¼ 1), second best (rank ¼ 2), etc. The higher the SUCRA score, the higher the overall mean rank for a particular BCG strain. There is a great deal of uncertainty associated with these relative rankings, and they must be interpreted within the context of the actual effect estimates computed from the network of trials.
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RESULTS
Clinical Trials and Patient Characteristics
A flowchart of the PRISMA search process is illustrated in figure 1. Initially our search yielded 262 potentially relevant publications. The titles of all 262 results were reviewed, and if the publication could not be eliminated based on title alone, the abstract was subsequently reviewed. The remaining 132 articles were reviewed in full to determine eligibility. 
Trial Characteristics
Risk of Bias
Risk of bias in contributing to the primary outcome of recurrence following BCG therapy was generally moderate ( fig. 2) . A large portion of the studies showed an unclear risk of selection, performance and detection bias (supplementary table 2, http:// jurology.com/). The majority of publications did not explicitly state any information concerning blinding, allocation concealment or randomization. Nevertheless, more than 85% of the series were considered low risk of bias when evaluating attrition and reporting bias. In addition, no major inclination was noted for small studies to overestimate or underestimate treatment effects. Networks considering the impact of BCG on disease recurrence with eligible comparisons considering all possible comparators are illustrated in figure 4 , A, which shows predominantly indirect comparisons of BCG against chemotherapy and a limited number of direct head-to-head comparisons among BCG strains. Networks considering chemotherapy as the common comparator are illustrated in figure 4 , B. In this final network meta-analysis Tokyo-172 (OR 0.39, 95% CI 0.16e0.93), Pasteur (OR 0.50, 95% CI 0.28e0.86) and TICE (OR 0.61, 95% CI 0.40e0.93) strains were associated with a decreased risk of recurrence compared to chemotherapy alone (table 2) . Tokyo-172 strain was associated with a nonsignificant decrease in disease recurrence compared to all BCG strains, while Connaught strain was associated with a nonsignificant increase in disease recurrence compared to Pasteur, TICE and Tokyo-172 BCG strains. SUCRA scoring identified Tokyo-172 strain as having the highest probability for superiority, followed by Pasteur, Figure 2 . Risk of bias graph TICE strain is the only BCG strain currently marketed in the United States, and the manufacturer of Connaught recently announced that it would cease production of BCG indefinitely. Ongoing manufacturing problems are a result of challenges in sustaining lots of BCG. 22 Resulting global shortages and BCG crises highlight the importance of understanding strain differences in determining treatment response since alternative strains are available. While it has been observed that these genetic differences between BCG vaccine strains can influence phenotypic properties such as immunogenicity and reactogenicity, 3 it is unclear if such strain differences influence the clinical efficacy of BCG in treating bladder cancer.
Recurrence
This study provides evidence of marked efficacy in preventing disease recurrence across BCG strains using direct and indirect comparisons from network meta-analysis. These findings are important as regulatory agencies including the FDA grapple with handling global BCG shortages due to manufacturing problems. In recent years the FDA has not approved requests for allowance of nonFDA approved BCG strains even in times of national BCG shortages due to lack of data regarding the oncologic efficacy of various daughter BCG strains. Importantly, we identified no evidence to support a statistically signficant difference in clinical efficacy across BCG strains.
The aforementioned genetic differences among the various strains can be traced back to 1921, when Calmette (a physician) and Gu erin (a veterinarian) from the Pasteur Institute in Paris cultivated an oral vaccine against tuberculosis through numerous 3 M. bovis was chosen because it is considered attenuated with respect to Mycobacterium tuberculosis due to loss of RD4 to RD11, the region of difference gene groups. This deletion leads to M. bovis and all subsequently derived BCG strains exhibiting resistance to pyrazinamide antibiotics. One additional deletion, RD1, remains the essential difference between BCG and its parent, M. bovis, responsible for encoding the protein secretion system ESX-1. This original vaccine was distributed worldwide in 1921 and continued to undergo serial passages using the method perfected by Calmette and Gu erin, leading to several additional mutations that created the wide assortment of BCG strains. This process continued until the early 1960s with the introduction of freeze-dried seed lots.
Despite these reported genetic differences among BCG strains, few trials have been conducted to compare the efficacy of different strains. We identified 5 randomized head-to-head trials comparing different BCG strains.
5e9 Four of these trials did not involve maintenance BCG therapy. Because maintenance BCG provides superior recurrence-free survival benefit compared to BCG therapy without maintenance, 23 results from these 4 trials may not be applicable to practices where maintenance BCG is standard of care. As an example, a provocative study found that 5-year recurrence-free survival was significantly improved in patients treated with BCG Connaught (74.0%) compared to those treated with BCG TICE (48.0%). 7 However, patients in that study were not routinely treated with maintenance BCG as is standard of care in the United States.
Interestingly the effect of specific BCG strains could be modified by use of maintenance therapy. Outcomes across strains have recently been reported in a large observational cohort of 2,099 patients with primary T1G3 bladder cancer treated with BCG TICE (599 patients) and Connaught (1, 546) . 24 When no maintenance treatment was given, Connaught was more effective than TICE regarding time to first recurrence (HR 1.34, p ¼ 0.004). However, when maintenance was given, TICE was more effective than Connaught regarding time to first recurrence (HR 0.64, p ¼ 0.01). In accordance with these findings our analysis suggests that Connaught strain is not superior to any other BCG strain. In fact, based on SUCRA scoring, Tokyo-172 was more than twice as likely to be the best treatment for NMIBC compared to other BCG strains, while Connaught ranked lower than Pasteur and TICE. Thus, studies evaluating differences in BCG strains should consider standard of care treatment patterns, including use of maintenance, which has consistently exhibited superiority over induction alone. 23, 25 As stated previously, Tokyo-172, Pasteur and TICE appear to rank first, second and third in efficacy overall, respectively, based on SUCRA values. However, the lack of evidence that one is clearly superior coupled with the wide confidence intervals for the odds ratios suggests prudence in attempting to draw definitive conclusions based on the existing evidence. The absence of sufficient numbers of head-to-head trials among these BCG strains also supports our conclusions that the evidence is insufficient to make definitive statements or recommendations about the relative superiority of a particular BCG strain over another.
Results from other head-to-head trials could be limited in ability to detect differences in efficacy due to insufficient sample size. A randomized controlled trial was initiated to compare Tokyo-172 vs Connaught but was closed before complete accrual. 8 Outcomes at a median followup of 2.4 years were reported for 129 patients, including 66 treated with Tokyo-172 and 63 treated with Connaught BCG strains. The study was powered to detect a recurrence-free survival difference of 0.2 (alpha 0.05, beta 0.2) with a sample size of 96 patients per arm. The complete response rates were 90.3% and 85.0% in patients given the Tokyo-172 and Connaught strains, respectively, which did not differ significantly (p ¼ 0.896). The 2-year recurrence-free survival rates were 73.2% and 68.8%, respectively.
Our analysis is subject to potential limitations. This analysis does not correct for important confounders such as interinstitutional bias, schedule of maintenance (3 weeks vs 1 week) or repeat transurethral resection for high grade T1 disease, which has now become standard practice. Also, due to nonstandardized and scant reporting of the effects of BCG strains on adverse events, we were unable to evaluate the tolerability of BCG strains and the extent to which this factor could influence ability to give complete doses.
Treatment toxicity is also an important component to be considered for BCG immunotherapy. However, a comparative effectiveness analysis is outside the scope of this meta-analysis. Complete response of CIS is a more definitive outcome parameter to evaluate. However, our results are based on recurrence of CIS and papillary lesions because there were too few studies of patients with only CIS to draw meaningful conclusions.
Many trials were included despite not using routine maintenance BCG, which, as discussed, could influence the overall interpretations of oncologic efficacy between strains. The risk of bias was unclear in many of the studies concerning selection bias due to underreporting of blinding and concealment procedures. Because many published reports provided only the number of patients experiencing disease recurrence, the odds of recurrence were determined without considering censoring or time to event. This analysis considered the effect of BCG strains but did not consider the effect of combination therapy. This issue could be addressed in future work as the efficacy of BCG may be improved through use of additional agents. 26 
CONCLUSIONS
The specific strain of BCG could influence bladder cancer recurrence rates. Use of Tokyo-172, Pasteur and TICE strains resulted in a significant decrease in recurrence compared to chemotherapy. However, no BCG strain was significantly superior to another strain during network analysis incorporating direct and indirect comparisons. Tokyo-172 strain was identified as having a high probability of superiority and should be compared to the more commonly used TICE and Connaught BCG strains.
